Would New Drug Launches Speed Up With A Pan-Asia Regulatory Framework? - Biopharma Asia Conference
This article was originally published in PharmAsia News
SINGAPORE - As diseases like diabetes and cardiovascular complications - previously believed to be more prevalent in Western nations - are progressively spreading East to places like India and China, Asia-based pharmaceutical companies are pushing for a pan-Asian regulatory regime that can benefit its people with clear and obtainable goals
You may also be interested in...
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings
SEOUL - U.S. FDA is encouraging regulatory counterparts in Asia Pacific Economic Cooperation forum countries to adopt a multi-layered approach to combat counterfeit drugs
SHANGHAI - The Association of Southeast Asian Nations is slated to implement common technical documents starting this year as part of "harmonized" pharmaceutical regulations in the region, which could benefit consumers by 2010